Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bioventus Inc. stock logo
BVS
Bioventus
$6.66
-0.4%
$6.81
$5.47
$14.38
$547.08M0.86450,890 shs358,334 shs
Paragon 28, Inc. stock logo
FNA
Paragon 28
$13.11
+0.1%
$13.10
$4.65
$13.13
$1.10B1.471.14 million shs19.38 million shs
GenMark Diagnostics, Inc. stock logo
GNMK
GenMark Diagnostics
$24.04
$24.02
$8.42
$24.25
$1.76B3.022.70 million shsN/A
Inari Medical, Inc. stock logo
NARI
Inari Medical
$79.97
$79.97
$39.76
$79.99
$4.68B1.021.41 million shsN/A
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bioventus Inc. stock logo
BVS
Bioventus
-0.45%+3.58%+1.99%-26.25%+18.93%
Paragon 28, Inc. stock logo
FNA
Paragon 28
0.00%0.00%0.00%+0.54%+108.68%
GenMark Diagnostics, Inc. stock logo
GNMK
GenMark Diagnostics
0.00%0.00%0.00%0.00%0.00%
Inari Medical, Inc. stock logo
NARI
Inari Medical
0.00%0.00%0.00%0.00%+72.02%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bioventus Inc. stock logo
BVS
Bioventus
2.5893 of 5 stars
3.30.00.00.00.04.21.3
Paragon 28, Inc. stock logo
FNA
Paragon 28
N/AN/AN/AN/AN/AN/AN/AN/A
GenMark Diagnostics, Inc. stock logo
GNMK
GenMark Diagnostics
N/AN/AN/AN/AN/AN/AN/AN/A
Inari Medical, Inc. stock logo
NARI
Inari Medical
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bioventus Inc. stock logo
BVS
Bioventus
2.67
Moderate Buy$14.33115.22% Upside
Paragon 28, Inc. stock logo
FNA
Paragon 28
2.20
Hold$12.75-2.71% Downside
GenMark Diagnostics, Inc. stock logo
GNMK
GenMark Diagnostics
0.00
N/AN/AN/A
Inari Medical, Inc. stock logo
NARI
Inari Medical
2.14
Hold$69.22-13.44% Downside

Current Analyst Ratings Breakdown

Latest GNMK, NARI, FNA, and BVS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/7/2025
Bioventus Inc. stock logo
BVS
Bioventus
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$15.00
(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bioventus Inc. stock logo
BVS
Bioventus
$567.70M0.96$0.53 per share12.58$2.80 per share2.38
Paragon 28, Inc. stock logo
FNA
Paragon 28
$256.18M4.29N/AN/A$2.05 per share6.39
GenMark Diagnostics, Inc. stock logo
GNMK
GenMark Diagnostics
$88.02M19.96N/AN/A$0.21 per share114.48
Inari Medical, Inc. stock logo
NARI
Inari Medical
$493.63M9.48$0.09 per share906.95$8.07 per share9.91
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bioventus Inc. stock logo
BVS
Bioventus
-$156.23M-$0.48N/A14.48N/A-7.11%15.61%4.01%N/A
Paragon 28, Inc. stock logo
FNA
Paragon 28
-$57.53M-$0.63N/AN/AN/A-25.31%-37.90%-18.22%N/A
GenMark Diagnostics, Inc. stock logo
GNMK
GenMark Diagnostics
-$47.35M-$0.82N/AN/AN/A-16.95%-39.36%-13.02%N/A
Inari Medical, Inc. stock logo
NARI
Inari Medical
-$1.64M-$1.35N/A727.00N/A-13.68%-10.09%-6.60%N/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bioventus Inc. stock logo
BVS
Bioventus
N/AN/AN/AN/AN/A
Paragon 28, Inc. stock logo
FNA
Paragon 28
N/AN/AN/AN/AN/A
GenMark Diagnostics, Inc. stock logo
GNMK
GenMark Diagnostics
N/AN/AN/AN/AN/A
Inari Medical, Inc. stock logo
NARI
Inari Medical
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bioventus Inc. stock logo
BVS
Bioventus
1.85
1.41
0.99
Paragon 28, Inc. stock logo
FNA
Paragon 28
0.79
3.50
1.60
GenMark Diagnostics, Inc. stock logo
GNMK
GenMark Diagnostics
0.75
4.33
3.84
Inari Medical, Inc. stock logo
NARI
Inari Medical
N/A
1.77
1.40

Institutional Ownership

CompanyInstitutional Ownership
Bioventus Inc. stock logo
BVS
Bioventus
62.94%
Paragon 28, Inc. stock logo
FNA
Paragon 28
63.57%
GenMark Diagnostics, Inc. stock logo
GNMK
GenMark Diagnostics
96.94%
Inari Medical, Inc. stock logo
NARI
Inari Medical
90.98%

Insider Ownership

CompanyInsider Ownership
Bioventus Inc. stock logo
BVS
Bioventus
33.00%
Paragon 28, Inc. stock logo
FNA
Paragon 28
15.32%
GenMark Diagnostics, Inc. stock logo
GNMK
GenMark Diagnostics
3.25%
Inari Medical, Inc. stock logo
NARI
Inari Medical
10.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bioventus Inc. stock logo
BVS
Bioventus
1,20082.14 million54.46 millionNot Optionable
Paragon 28, Inc. stock logo
FNA
Paragon 28
343,00083.94 million70.89 millionOptionable
GenMark Diagnostics, Inc. stock logo
GNMK
GenMark Diagnostics
61873.09 millionN/AOptionable
Inari Medical, Inc. stock logo
NARI
Inari Medical
80058.54 million52.34 millionOptionable

Recent News About These Companies

FDA grants 510(k) clearance to Stryker’s total ankle system
The top nitinol cardiac medtech news of 2025 (so far)
8 spine, orthopedic acquisitions in Q1
Wearable defibrillator maker Kestra Medical plots $150M IPO
Stryker grows cardiovascular division with Inari Medical acquisition
Stryker Completes Acquisition of Inari
Stryker concludes Inari Medical acquisition for $4.9bn
Stryker completes Inari Medical acquisition

Media Sentiment Over Time

Top Headlines

View All Headlines
Bioventus stock logo

Bioventus NYSE:BVS

$6.66 -0.03 (-0.45%)
Closing price 06/26/2025 04:00 PM Eastern
Extended Trading
$6.62 -0.04 (-0.66%)
As of 06/26/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.

Paragon 28 stock logo

Paragon 28 NYSE:FNA

$13.10 +0.02 (+0.11%)
Closing price 04/17/2025
Extended Trading
$13.10 0.00 (0.00%)
As of 04/17/2025 05:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Paragon 28, Inc. develops, distributes, and sells foot and ankle surgical systems in the United States and internationally. It offers plating systems, including gorilla plating systems, such as lisfranc, lapidus, lateral column, calcaneus slide, and naviculocuneiform (NC) fusion plating systems; baby gorilla plate-specific screws, navicular fracture plates, and 5th metatarsal hook plates; and silverback plating systems. The company also provides precision guide technology for various procedures consisting of fusion, a procedure to address bunion deformities that fuses two bones on the big toe; first tarsometatarsal arthrodesis; and metatarsal osteotomy for bunion correction, medial column beaming for charcot foot reconstruction, ankle fusion plating, and NC joint arthrodesis. In addition, it offers monster, mini monster, and joust beaming screw systems for use in bone reconstruction, osteotomy, arthrodesis, joint fusion, ligament fixation, fracture repair, and fracture fixation; APEX 3D total ankle replacement systems; and total talus spacers to replace the talus and bone in the ankle that connects the leg and foot. Further, the company provides forefoot or hallux valgus correction systems, including phantom intramedullary nail systems for the treatment of severe hallux valgus; and various orthobiologics comprising bone wedges, grafts, demineralized bone matrices, bone void fillers, synthetic materials, amniotic products, and a biocompatible collagen matrix, as well as PRESERVE bone graft systems for homologous application. Additionally, it offers soft tissue fixation systems, titanium sprayed polyetheretherketone implants, nitinol staple systems, stabilization systems, and curved instruments. The company serves hospitals and ambulatory surgery centers through a network of sales representatives and stocking distributors. Paragon 28, Inc. was founded in 2010 and is headquartered in Englewood, Colorado.

GenMark Diagnostics stock logo

GenMark Diagnostics NASDAQ:GNMK

GenMark Diagnostics, Inc., a molecular diagnostics company, engages in the developing and commercializing molecular panels based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument and respiratory pathogen panel, which integrates automated nucleic acid extraction and amplification with its eSensor technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results. The company also offers Blood Culture Identification Gram-Positive and Negative panel, Blood Culture Identification Fungal Pathogen panel, and ePlex Gastrointestinal Pathogen Panel. In addition, it provides XT-8 instrument, and related diagnostic and research tests, as well as certain custom manufactured reagents to support a range of molecular tests with a workstation and disposable test cartridges. Further, the company offers diagnostic tests for use with its XT-8 system that includes respiratory viral panel, cystic fibrosis genotyping test, warfarin sensitivity test, thrombophilia risk test, and hepatitis C virus genotyping test and associated custom manufactured reagents, as well as 2C19 genotyping test and eSensor SARS-CoV-2 Test. GenMark Diagnostics, Inc. sells its products through direct sales and technically specialized service organization in the United States, Europe, and internationally. The company was incorporated in 2010 and is headquartered in Carlsbad, California.

Inari Medical stock logo

Inari Medical NASDAQ:NARI

$79.97 0.00 (0.00%)
As of 02/19/2025

Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation. It serves interventional radiologists, interventional cardiologists, and vascular surgeons. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.